Glucagon-like peptide-1 (GLP-1) receptor agonists are driving the largest structural shift in the pharmaceutical market in over a decade. Beyond obesity management, clinical trials demonstrate broad therapeutic utility across cardiovascular and renal indications.
MedTech and Device Portfolio Realignment
Medical technology companies are recalibrating long-term growth models for bariatric surgery devices and continuous glucose monitors. While surgical volumes show early signs of deceleration, therapeutic adherence challenges may preserve demand for secondary interventions.
Manufacturing Scale and Supply Bottlenecks
Contract development and manufacturing organizations (CDMOs) are expanding fill-finish capacity to address persistent market deficits. Capital spending on specialized sterile injectable lines is projected to remain elevated through 2028.